CN116075238B - 用于个体化治疗方法的制剂 - Google Patents

用于个体化治疗方法的制剂

Info

Publication number
CN116075238B
CN116075238B CN202180057236.7A CN202180057236A CN116075238B CN 116075238 B CN116075238 B CN 116075238B CN 202180057236 A CN202180057236 A CN 202180057236A CN 116075238 B CN116075238 B CN 116075238B
Authority
CN
China
Prior art keywords
salt
composition
present disclosure
amino acid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180057236.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN116075238A (zh
Inventor
奥利弗·D·K·马多克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feisi Treatment Co
Original Assignee
Feisi Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feisi Treatment Co filed Critical Feisi Treatment Co
Priority to CN202511487589.7A priority Critical patent/CN121445725A/zh
Publication of CN116075238A publication Critical patent/CN116075238A/zh
Application granted granted Critical
Publication of CN116075238B publication Critical patent/CN116075238B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180057236.7A 2020-06-03 2021-06-02 用于个体化治疗方法的制剂 Active CN116075238B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511487589.7A CN121445725A (zh) 2020-06-03 2021-06-02 用于个体化治疗方法的制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034137P 2020-06-03 2020-06-03
US63/034,137 2020-06-03
PCT/US2021/035476 WO2021247724A1 (en) 2020-06-03 2021-06-02 Formulations for personalized methods of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511487589.7A Division CN121445725A (zh) 2020-06-03 2021-06-02 用于个体化治疗方法的制剂

Publications (2)

Publication Number Publication Date
CN116075238A CN116075238A (zh) 2023-05-05
CN116075238B true CN116075238B (zh) 2025-11-04

Family

ID=78829914

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180057236.7A Active CN116075238B (zh) 2020-06-03 2021-06-02 用于个体化治疗方法的制剂
CN202511487589.7A Pending CN121445725A (zh) 2020-06-03 2021-06-02 用于个体化治疗方法的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511487589.7A Pending CN121445725A (zh) 2020-06-03 2021-06-02 用于个体化治疗方法的制剂

Country Status (7)

Country Link
US (2) US12220402B2 (https=)
EP (1) EP4161501A4 (https=)
JP (1) JP2023530235A (https=)
CN (2) CN116075238B (https=)
AU (1) AU2021283293B2 (https=)
CA (1) CA3181158A1 (https=)
WO (1) WO2021247724A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
CN114947139A (zh) * 2022-04-28 2022-08-30 成都尚医信息科技有限公司 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用
CN117159528A (zh) * 2023-01-13 2023-12-05 再造再生健康科技(杭州)有限公司 用于促进提高内源类胰岛素样生长因子1分泌的组合物
WO2025029650A1 (en) 2023-07-28 2025-02-06 Li Xiyan Nutritionally modified diets comprising aminoacids for use in treating a disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016132A1 (en) * 2019-07-19 2021-01-28 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832465A (en) * 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US4734401A (en) 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
US4988724A (en) 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
IT1289754B1 (it) * 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6713501B1 (en) 1998-03-13 2004-03-30 The Johns Hopkins University Supplement for dialysis patients
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
US20030129262A1 (en) 2001-08-30 2003-07-10 Epner Daniel E. Methionine restriction for cancer therapy
JP4836044B2 (ja) 2004-04-02 2011-12-14 味の素株式会社 経口アミノ酸ニキビ治療剤
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US20060280840A1 (en) 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007133642A1 (en) 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US20100151062A1 (en) 2008-12-16 2010-06-17 Bruno Stefanon Determining nutrients for animals through gene expression
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
BR112012009423A2 (pt) 2009-10-22 2017-06-13 Univ Southern California método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
CN103068381A (zh) 2010-08-11 2013-04-24 兴和株式会社 用于肝细胞癌的预防和／或治疗的医药
JP2014512803A (ja) * 2011-02-23 2014-05-29 ムドスーレ エルティディ 個人的腫瘍プロファイリング治療のための組成物及び方法
WO2012135714A2 (en) 2011-03-30 2012-10-04 Whitehead Institute For Biomedical Research Serine biosynthesis pathway inhibition for treatment of cancer
CN103184208B (zh) 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
WO2014049566A2 (en) 2012-09-28 2014-04-03 Stellenbosch University Nutritional kit
US20140170259A1 (en) * 2012-12-14 2014-06-19 Mead Johnson Nutrition Company Nutritional composition for promoting satiety
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
WO2016003263A1 (en) * 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
CA2976106A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
EP3352586A4 (en) 2015-09-21 2019-05-15 The Board Of Trustees Of The Leland Stanford Junior University NUTRITIONAL TREATMENT FOR CANCER DISEASES
CN109069462A (zh) * 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
CA3119300A1 (en) 2017-11-13 2019-05-16 Cancer Research Technology Ltd. Dietary product
EP3723772A4 (en) 2017-12-11 2021-09-08 Filtricine, Inc. COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY
US20190177651A1 (en) 2017-12-12 2019-06-13 Afton Chemical Corporation Lubricant compositions comprising olefin copolymer dispersants in combination with additives
GB201807155D0 (en) * 2018-05-01 2018-06-13 Liverpool Womens Trust Nhs Found Trust Neonatal Parenteral nutrition formulations
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
EP4181914A2 (en) 2020-07-15 2023-05-24 The Trustees of Princeton University Ketogenic diet and ketone supplementation for cancer therapy
JP7727286B2 (ja) 2020-09-23 2025-08-21 アミノヴィタ エセ．エレ． 癌の代謝療法
JP2024504260A (ja) 2020-12-16 2024-01-31 フェイス セラピューティクス インコーポレイテッド セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法
WO2023130140A2 (en) 2022-01-03 2023-07-06 Faeth Therapeutics, Inc. Personalized methods of treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016132A1 (en) * 2019-07-19 2021-01-28 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Amino Acids Diets as Model for Investigating Cancer Induced by Acrylamide Produced during Wrong Food Cooking";GAMAL M HAMAD;《SOJ BIOCHEMISTRY》;20180219;第4卷(第1期);第1-14页 *

Also Published As

Publication number Publication date
CA3181158A1 (en) 2021-12-09
US20250367169A1 (en) 2025-12-04
JP2023530235A (ja) 2023-07-14
AU2021283293A1 (en) 2023-01-19
CN116075238A (zh) 2023-05-05
AU2021283293B2 (en) 2025-06-26
US12220402B2 (en) 2025-02-11
WO2021247724A1 (en) 2021-12-09
EP4161501A1 (en) 2023-04-12
CN121445725A (zh) 2026-02-03
US20220117943A1 (en) 2022-04-21
EP4161501A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
CN116075238B (zh) 用于个体化治疗方法的制剂
CN100355420C (zh) 富含亮氨酸的营养组合物
CN109222103B (zh) 增肌组合物和保健食品
Etani et al. Selenium deficiency in children and adolescents nourished by parenteral nutrition and/or selenium-deficient enteral formula
EP4253526A1 (en) Novel bifidobacterium animalis subsp. lactis hem20-01 strain, and composition for treating depression comprising same or culture thereof
BR112018010200B1 (pt) Dose de um suplemento alimentar, uso da dose do suplemento alimentar, e composição alimentar.
Mok et al. Glutamine supplementation in sick children: is it beneficial?
TW201829017A (zh) 於消化道之吸收降低的改善用組成物、及於消化道之吸收的促進用組成物
US11419915B2 (en) Compositions and methods for the treatment of malnutrition
DE20207569U1 (de) Diätetische und pharmazeutische Zusammensetzungen
JP2019108364A (ja) 栄養組成物
RU2462244C2 (ru) Композиция для лечения неинфекционного воспаления
WO2018085440A1 (en) Reduction and prevention of muscle loss by conjugated linoleic acid (cla) and vitamin d
JP6159382B2 (ja) 経口紫外線抵抗性向上剤
US20190298721A1 (en) Stable pro-vitamin derivative compounds, pharmaceutical and dietary compositions, and methods of their use
WO2021173950A1 (en) Sweetener and manufacturing process therefor
JP2010254645A (ja) 経口紫外線抵抗性向上剤
JP2013170158A (ja) 経口紫外線抵抗性向上剤
HK1108563B (zh) 富含亮氨酸的营养组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: texas

Applicant after: Feisi Treatment Co.

Address before: California, USA

Applicant before: Feisi Treatment Co.

GR01 Patent grant
GR01 Patent grant